-
公开(公告)号:SK284349B6
公开(公告)日:2005-02-04
申请号:SK152597
申请日:1997-11-13
Applicant: HOECHST AG
Inventor: STILZ HANS ULRICH , WEHNER VOLKMAR , HULS CHRISTOPH , SEIFFGE DIRK
IPC: A61K31/415 , A61K31/4166 , A61K38/00 , A61K38/05 , A61K38/06 , A61K38/07 , A61P3/08 , A61P9/00 , A61P9/10 , C07D233/76 , A61P11/00 , A61P19/02 , A61P29/00 , A61P33/02 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D233/54 , C07D233/72 , C07K5/02 , C07K5/023 , C07K5/06 , C07K5/08 , C07K5/10 , C07K5/117 , C07D207/02 , C07D233/02
Abstract: Compounds of general formula (I), which are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4, the pharmaceutical preparation containing thereof and their use. Compounds of general formula (I) are useful for the preparation of medicaments intended for the treatment or prophylaxis of diseases which are caused by an undesired extent of leukocyte adhesion and/or leukocyte migration or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands, for example of inflammatory processes, rheumatoid arthritis or allergic disorders.
-
2.
公开(公告)号:AU4515997A
公开(公告)日:1998-05-21
申请号:AU4515997
申请日:1997-11-13
Applicant: HOECHST AG
Inventor: STILZ HANS ULRICH , WEHNER VOLKMAR , KNOLLE JOCHEN , BARTNIK ECKART , HULS CHRISTOPH
IPC: C07D233/00 , A61K31/415 , A61K31/4166 , A61K31/4178 , A61K31/421 , A61K31/426 , A61K38/00 , A61K38/06 , A61K38/07 , A61K38/39 , A61P3/08 , A61P9/00 , A61P9/10 , A61P11/00 , A61P19/02 , A61P29/00 , A61P33/02 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D233/32 , C07D233/72 , C07D233/74 , C07D233/76 , C07D233/86 , C07D257/00 , C07D403/12 , C07D405/12 , C07K5/02 , C07K5/023 , C07K5/078 , C07K5/08 , C07K5/097 , C07K5/10 , C07K5/117 , C07K7/06 , C07K14/78
Abstract: Use of N-substituted pyrrolidone, imidazolidinone, oxazolidinone or thiazolidinone derivatives of formula (I), in all stereoisomer (or mixture) forms, or their salts for inhibiting the adhesion and/or migration of leukocytes or inhibiting VLA-4 receptors is new. W = R1-A-CR13 or R1A-CH=C; Y = CO, CS or CH2; Z = O, S or CH2 etc.; A = 1-6C alkylene, 3-7C cycloalkylene, (1-6C) alkylene-phenylene, or the divalent residue of a 5- or 6-membered ring containing 1 or 2 N (optionally substituted); B = 1-6C alkylene (optionally substituted), 2-6C alkenylene, phenylene, phenylene-(1-3C) alkyl or (1-3C) alkylene-phenylene; D = CR2R3, NR3 or CH=CR3; E = tetrazolyl, SO3H etc.; R = H, alkyl, 3-8C cycloalkyl, Ar or Ar-alkyl ; R1 = X-NH-C(=NH)-(CH2)p or X1-NH-(CH2)p; p = 0-3; X = H, 1-6C alkyl, (1-6C) alkylcarbonyl, Ar-(1-6C) alkoxycarbonyl, CN, OH, etc.; X1 = X etc.; R2 = H, alkyl, Ar, Ar-alkyl or 3-8C cycloalkyl; R3 = H, alkyl, Ar, alkenyl, alkynyl, pyridyl etc.; R13 = H, 1-6C alkyl, Ar-alkyl or 3-8C cycloalkyl; b, c, d, f = 0 or 1, but not all 0; e, g, h= 0-6; Ar = optionally substituted 6-14C aryl; unless specified otherwise alkyl moieties have 1-8C, alkenyl or alkynyl moieties 2-8C, cycloalkyl moieties 3-12C and bi- or tri-cycloalkyl moieties 6-12C.
-
公开(公告)号:AU4515597A
公开(公告)日:1998-05-21
申请号:AU4515597
申请日:1997-11-13
Applicant: HOECHST AG
Inventor: STILZ HANS ULRICH , WEHNER VOLKMAR , HULS CHRISTOPH , SEIFFGE DIRK
IPC: C07D277/20 , A61K38/00 , A61K38/05 , A61K38/06 , A61K38/07 , A61P3/08 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P19/02 , A61P29/00 , A61P33/02 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D233/54 , C07D233/72 , C07D277/34 , C07K5/06 , C07K5/078 , C07K5/097 , C07K5/107 , C07K5/11 , C07K5/117 , A61K31/415
Abstract: Use of N-substituted pyrrolidone, imidazolidinone, oxazolidinone or thiazolidinone derivatives of formula (I), in all stereoisomer or mixture forms, or their salts as medicaments is new. W = R1-A-CR13 or R1A-CH=C; Y = CO, CS or CH2; Z = O, S or CH2 etc.; A = direct bond, 3-12C cycloalkylene, (1-6C) alkylene-(3-12C) cycloalkylene, phenylene, or the divalent residue of a 5- or 6-membered ring containing 1 or 2 N (optionally mono- or disubstituted) etc.; B = 1-6C alkylene (optionally substituted), 2-6C alkenylene, phenylene, phenylene-(1-3C) alkyl or (1-3C) alkylene-phenylene; D = CR2R3, NR3 or CH=CR3; E = tetrazolyl, SO3H etc.; R = H, alkyl, cycloalkyl, cycloalkylalkyl, Ar, Ar-alkyl, Het' or Het '-alkyl (where alkyl residues are optionally substituted by one or more F); R1 = SR21, SSR21, SOR22, SO2R22, S-OR21, SO-OR21, SO2-OR21, SCOR21, SCOOR22, SCSSR22, OCOR21, OCSR21, OCOOR22, OSO2R22, OSO-R22, OP(O)(OR21)2, P(O)(OR21)2, P(O)(R22)OR21, CN, halo etc.; R2 = H, alkyl, Ar, Ar-alkyl or 3-8C cycloalkyl; R3 = H, alkyl, Ar, Ar-alkyl, 3-8C cycloalkyl, alkenyl, alkynyl, alkenylcarbonyl, alkynylcarbonyl, pyridyl etc.; R13 = H, 1-6C alkyl, Ar, Ar-alkyl, 3-8C cycloalkyl or (3-8C) cycloalkylalkyl; R21 = H, alkyl, hydroxyalkyl, alkenyl, cycloalkyl, cycloalkylalkyl, Ar, Ar-alkyl, Het' or Het'-alkyl (where alkyl residues are optionally substituted by one or more F); b, c, d, f = 0 or 1 provided not all are 0; e, g,h = 0-6; Ar = optionally substituted 6-14C aryl; Het' = optionally substituted heteroaryl; unless specified otherwise alkyl moieties have 1-8C, alkenyl or alkynyl moieties 2-8C, cycloalkyl moieties 3-12C and bi- or tri-cycloalkyl moieties 6-12C.
-
公开(公告)号:CA2220777C
公开(公告)日:2012-05-29
申请号:CA2220777
申请日:1997-11-12
Applicant: HOECHST AG
Inventor: STILZ HANS ULRICH , WEHNER VOLKMAR , HULS CHRISTOPH , SEIFFGE DIRK
IPC: C07D277/20 , C07K5/072 , A61K31/415 , A61K38/00 , A61K38/05 , A61K38/06 , A61K38/07 , A61P3/08 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P19/02 , A61P29/00 , A61P33/02 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D233/54 , C07D233/72 , C07D233/76 , C07D277/34 , C07K5/06 , C07K5/078 , C07K5/097 , C07K5/107 , C07K5/11 , C07K5/117
Abstract: The present invention relates to compounds of the formula I (see formula I) which are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 which belongs to the group of integrins. The invention also relates to processes for their preparation, to the use of compounds of the formula I for the treatment or prophylaxis of diseases which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or which are associated therewith or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part, for example of inflammatory processes, of rheumatoid arthritis or of allergic disorders, and also to the use of compounds of the formula I for the production of pharmaceuticals for use in such diseases, and to pharmaceutical preparations which contain the compounds of the formula I.
-
公开(公告)号:AU736595B2
公开(公告)日:2001-08-02
申请号:AU4525797
申请日:1997-11-13
Applicant: HOECHST AG
Inventor: STILZ HANS ULRICH , WEHNER VOLKMAR , HULS CHRISTOPH , SEIFFGE DIRK
IPC: C07D233/76 , A61K31/415 , A61K31/4166 , A61K38/00 , A61K38/05 , A61K38/06 , A61K38/07 , A61P3/08 , A61P9/00 , A61P9/10 , A61P11/00 , A61P19/02 , A61P29/00 , A61P33/02 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D233/54 , C07D233/72 , C07K5/02 , C07K5/023 , C07K5/06 , C07K5/08 , C07K5/10 , C07K5/117 , C07K5/083 , C07K5/062
Abstract: Use of N-substituted pyrrolidone, imidazolidinone, oxazolidinone or thiazolidinone derivatives of formula (I), in all stereoisomer or mixture forms, or their salts is for inhibiting the adhesion and/or migration of leukocytes or inhibiting VLA-4 receptors is new. W = R1-A-CR13 or R1A-CH=C; Y = CO, CS or CH2; Z = O, S or CH2 etc.; A = 1-6C alkylene, 3-12C cycloalkylene, (1-6C), phenylene-(1-6C)alkyl, or the divalent residue of a 5- or 6-membered ring containing 1 or 2 N (optionally mono- or disubstituted) etc.; B = 1-6C alkylene (optionally substituted), 2-6C alkenylene, phenylene, phenylene-(1-3C) alkyl or (1-3C) alkylene-phenyl; D = CR2R3. NR3 or CH=CR3; E = tetrazolyl, SO3H etc.; R = H, alkyl, cycloalkyl, cycloalkylalkyl, Ar, Ar-alkyl, Het' or Het'-alkyl (where alkyl residues are optionally substituted); R1 = H, 1-10C alkyl (optionally fluorinated), cycloalkyl, cycloalkylalkyl, O or S etc.; R2 = H, alkyl, Ar, Ar-alkyl or 3-8C cycloalkyl; R3 = H, alkyl, Ar, Ar-alkyl, 3-8C cycloalkyl, alkenyl, alkynyl, alkenylcarbonyl, alkynylcarbonyl, pyridyl etc.; R13 = H, 1-6C alkyl, Ar-alkyl or 3-8C cycloalkyl; b, c, d, f = 0 or 1, but not all 0; e, g, h= 0-6; Ar = optionally substituted 6-14C aryl; Het' = optionally substituted heteroaryl; unless specified otherwise alkyl moieties have 1-8C, alkenyl or alkynyl moieties 2-8C, cycloalkyl moieties 3-12C and bi- or tri-cycloalkyl moieties 6-12C.
-
公开(公告)号:NZ329177A
公开(公告)日:1998-11-25
申请号:NZ32917797
申请日:1997-11-13
Applicant: HOECHST AG
Inventor: STILZ HANS ULRICH , WEHNER VOLKMAR , HULS CHRISTOPH , SEIFFGE DIRK
IPC: A61K31/415 , A61K31/4166 , A61K38/00 , A61K38/05 , A61K38/06 , A61K38/07 , C07D233/76 , A61P3/08 , A61P9/00 , A61P9/10 , A61P11/00 , A61P19/02 , A61P29/00 , A61P33/02 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D233/54 , C07D233/72 , C07K5/02 , C07K5/023 , C07K5/06 , C07K5/08 , C07K5/10 , C07K5/117
Abstract: Use of N-substituted pyrrolidone, imidazolidinone, oxazolidinone or thiazolidinone derivatives of formula (I), in all stereoisomer or mixture forms, or their salts is for inhibiting the adhesion and/or migration of leukocytes or inhibiting VLA-4 receptors is new. W = R1-A-CR13 or R1A-CH=C; Y = CO, CS or CH2; Z = O, S or CH2 etc.; A = 1-6C alkylene, 3-12C cycloalkylene, (1-6C), phenylene-(1-6C)alkyl, or the divalent residue of a 5- or 6-membered ring containing 1 or 2 N (optionally mono- or disubstituted) etc.; B = 1-6C alkylene (optionally substituted), 2-6C alkenylene, phenylene, phenylene-(1-3C) alkyl or (1-3C) alkylene-phenyl; D = CR2R3. NR3 or CH=CR3; E = tetrazolyl, SO3H etc.; R = H, alkyl, cycloalkyl, cycloalkylalkyl, Ar, Ar-alkyl, Het' or Het'-alkyl (where alkyl residues are optionally substituted); R1 = H, 1-10C alkyl (optionally fluorinated), cycloalkyl, cycloalkylalkyl, O or S etc.; R2 = H, alkyl, Ar, Ar-alkyl or 3-8C cycloalkyl; R3 = H, alkyl, Ar, Ar-alkyl, 3-8C cycloalkyl, alkenyl, alkynyl, alkenylcarbonyl, alkynylcarbonyl, pyridyl etc.; R13 = H, 1-6C alkyl, Ar-alkyl or 3-8C cycloalkyl; b, c, d, f = 0 or 1, but not all 0; e, g, h= 0-6; Ar = optionally substituted 6-14C aryl; Het' = optionally substituted heteroaryl; unless specified otherwise alkyl moieties have 1-8C, alkenyl or alkynyl moieties 2-8C, cycloalkyl moieties 3-12C and bi- or tri-cycloalkyl moieties 6-12C.
-
公开(公告)号:SK152697A3
公开(公告)日:1998-06-03
申请号:SK152697
申请日:1997-11-13
Applicant: HOECHST AG
Inventor: STILZ HANS U , WEHNER VOLKMAR , KNOLLE JOCHEN , BARTNIK ECKART , HULS CHRISTOPH
IPC: A61K31/415 , A61K31/4166 , A61K31/4178 , A61K31/421 , A61K31/426 , A61K38/00 , A61K38/06 , A61K38/07 , C07D233/00 , A61K38/39 , A61P3/08 , A61P9/00 , A61P9/10 , A61P11/00 , A61P19/02 , A61P29/00 , A61P33/02 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D233/32 , C07D233/72 , C07D233/74 , C07D233/76 , C07D233/86 , C07D257/00 , C07D403/12 , C07D405/12 , C07K5/02 , C07K5/023 , C07K5/078 , C07K5/08 , C07K5/097 , C07K5/10 , C07K5/117 , C07K7/06 , C07K14/78 , C07D207/00 , C07D263/02 , C07D277/02 , A61K31/40 , A61K31/42 , A61K31/425
Abstract: Use of N-substituted pyrrolidone, imidazolidinone, oxazolidinone or thiazolidinone derivatives of formula (I), in all stereoisomer (or mixture) forms, or their salts for inhibiting the adhesion and/or migration of leukocytes or inhibiting VLA-4 receptors is new. W = R1-A-CR13 or R1A-CH=C; Y = CO, CS or CH2; Z = O, S or CH2 etc.; A = 1-6C alkylene, 3-7C cycloalkylene, (1-6C) alkylene-phenylene, or the divalent residue of a 5- or 6-membered ring containing 1 or 2 N (optionally substituted); B = 1-6C alkylene (optionally substituted), 2-6C alkenylene, phenylene, phenylene-(1-3C) alkyl or (1-3C) alkylene-phenylene; D = CR2R3, NR3 or CH=CR3; E = tetrazolyl, SO3H etc.; R = H, alkyl, 3-8C cycloalkyl, Ar or Ar-alkyl ; R1 = X-NH-C(=NH)-(CH2)p or X1-NH-(CH2)p; p = 0-3; X = H, 1-6C alkyl, (1-6C) alkylcarbonyl, Ar-(1-6C) alkoxycarbonyl, CN, OH, etc.; X1 = X etc.; R2 = H, alkyl, Ar, Ar-alkyl or 3-8C cycloalkyl; R3 = H, alkyl, Ar, alkenyl, alkynyl, pyridyl etc.; R13 = H, 1-6C alkyl, Ar-alkyl or 3-8C cycloalkyl; b, c, d, f = 0 or 1, but not all 0; e, g, h= 0-6; Ar = optionally substituted 6-14C aryl; unless specified otherwise alkyl moieties have 1-8C, alkenyl or alkynyl moieties 2-8C, cycloalkyl moieties 3-12C and bi- or tri-cycloalkyl moieties 6-12C.
-
公开(公告)号:MX9604657A
公开(公告)日:1998-04-30
申请号:MX9604657
申请日:1996-10-08
Applicant: HOECHST AG
Inventor: TOEPFER ALEXANDER , KRETZSCHMAR GERHARD , SCHOLKENS BERNWARD , KLEMM PETER , HULS CHRISTOPH , SEIFFGE DIRK
IPC: A61K31/215 , C07D295/20 , A61K31/33 , A61K31/40 , A61K31/435 , A61K31/445 , A61K31/495 , A61K31/70 , A61K31/7028 , A61K31/7034 , A61P3/08 , A61P9/00 , A61P9/08 , A61P9/10 , A61P11/00 , A61P17/00 , A61P29/00 , A61P35/00 , A61P37/06 , A61P37/08 , A61P43/00 , C07D207/08 , C07D207/16 , C07D211/34 , C07D211/62 , C07D405/00 , C07H15/203 , C07H15/207 , C07H17/00 , C07H19/04 , C07D405/10
Abstract: La invencion se refiere a conjugados que consisten en derivados de piperidina o pirrolidina una o varias veces carboxilados y en piranosas, furanosas o polialcoholes enlazados a través de una cadena o un ciclo. Los grupos carboxilo de los derivados de piperidina pueden asentarse directamente en el anillo o estar enlazados con el anillo a través de una cadena corta. La invencion se refiere, además, a la preparacion de estos compuestos, así como a su empleo para la preparacion de medicamentos y agentes de diagnostico.
-
公开(公告)号:AU4525797A
公开(公告)日:1998-05-21
申请号:AU4525797
申请日:1997-11-13
Applicant: HOECHST AG
Inventor: STILZ HANS ULRICH , WEHNER VOLKMAR , HULS CHRISTOPH , SEIFFGE DIRK
IPC: C07D233/76 , A61K31/415 , A61K31/4166 , A61K38/00 , A61K38/05 , A61K38/06 , A61K38/07 , A61P3/08 , A61P9/00 , A61P9/10 , A61P11/00 , A61P19/02 , A61P29/00 , A61P33/02 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D233/54 , C07D233/72 , C07K5/02 , C07K5/023 , C07K5/06 , C07K5/08 , C07K5/10 , C07K5/117 , C07K5/083 , C07K5/062
Abstract: Use of N-substituted pyrrolidone, imidazolidinone, oxazolidinone or thiazolidinone derivatives of formula (I), in all stereoisomer or mixture forms, or their salts is for inhibiting the adhesion and/or migration of leukocytes or inhibiting VLA-4 receptors is new. W = R1-A-CR13 or R1A-CH=C; Y = CO, CS or CH2; Z = O, S or CH2 etc.; A = 1-6C alkylene, 3-12C cycloalkylene, (1-6C), phenylene-(1-6C)alkyl, or the divalent residue of a 5- or 6-membered ring containing 1 or 2 N (optionally mono- or disubstituted) etc.; B = 1-6C alkylene (optionally substituted), 2-6C alkenylene, phenylene, phenylene-(1-3C) alkyl or (1-3C) alkylene-phenyl; D = CR2R3. NR3 or CH=CR3; E = tetrazolyl, SO3H etc.; R = H, alkyl, cycloalkyl, cycloalkylalkyl, Ar, Ar-alkyl, Het' or Het'-alkyl (where alkyl residues are optionally substituted); R1 = H, 1-10C alkyl (optionally fluorinated), cycloalkyl, cycloalkylalkyl, O or S etc.; R2 = H, alkyl, Ar, Ar-alkyl or 3-8C cycloalkyl; R3 = H, alkyl, Ar, Ar-alkyl, 3-8C cycloalkyl, alkenyl, alkynyl, alkenylcarbonyl, alkynylcarbonyl, pyridyl etc.; R13 = H, 1-6C alkyl, Ar-alkyl or 3-8C cycloalkyl; b, c, d, f = 0 or 1, but not all 0; e, g, h= 0-6; Ar = optionally substituted 6-14C aryl; Het' = optionally substituted heteroaryl; unless specified otherwise alkyl moieties have 1-8C, alkenyl or alkynyl moieties 2-8C, cycloalkyl moieties 3-12C and bi- or tri-cycloalkyl moieties 6-12C.
-
公开(公告)号:AU736725B2
公开(公告)日:2001-08-02
申请号:AU4515597
申请日:1997-11-13
Applicant: HOECHST AG
Inventor: STILZ HANS ULRICH , WEHNER VOLKMAR , HULS CHRISTOPH , SEIFFGE DIRK
IPC: C07D277/20 , A61K38/00 , A61K38/05 , A61K38/06 , A61K38/07 , A61P3/08 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P19/02 , A61P29/00 , A61P33/02 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D233/54 , C07D233/72 , C07D277/34 , C07K5/06 , C07K5/078 , C07K5/097 , C07K5/107 , C07K5/11 , C07K5/117 , A61K31/415
Abstract: Use of N-substituted pyrrolidone, imidazolidinone, oxazolidinone or thiazolidinone derivatives of formula (I), in all stereoisomer or mixture forms, or their salts as medicaments is new. W = R1-A-CR13 or R1A-CH=C; Y = CO, CS or CH2; Z = O, S or CH2 etc.; A = direct bond, 3-12C cycloalkylene, (1-6C) alkylene-(3-12C) cycloalkylene, phenylene, or the divalent residue of a 5- or 6-membered ring containing 1 or 2 N (optionally mono- or disubstituted) etc.; B = 1-6C alkylene (optionally substituted), 2-6C alkenylene, phenylene, phenylene-(1-3C) alkyl or (1-3C) alkylene-phenylene; D = CR2R3, NR3 or CH=CR3; E = tetrazolyl, SO3H etc.; R = H, alkyl, cycloalkyl, cycloalkylalkyl, Ar, Ar-alkyl, Het' or Het '-alkyl (where alkyl residues are optionally substituted by one or more F); R1 = SR21, SSR21, SOR22, SO2R22, S-OR21, SO-OR21, SO2-OR21, SCOR21, SCOOR22, SCSSR22, OCOR21, OCSR21, OCOOR22, OSO2R22, OSO-R22, OP(O)(OR21)2, P(O)(OR21)2, P(O)(R22)OR21, CN, halo etc.; R2 = H, alkyl, Ar, Ar-alkyl or 3-8C cycloalkyl; R3 = H, alkyl, Ar, Ar-alkyl, 3-8C cycloalkyl, alkenyl, alkynyl, alkenylcarbonyl, alkynylcarbonyl, pyridyl etc.; R13 = H, 1-6C alkyl, Ar, Ar-alkyl, 3-8C cycloalkyl or (3-8C) cycloalkylalkyl; R21 = H, alkyl, hydroxyalkyl, alkenyl, cycloalkyl, cycloalkylalkyl, Ar, Ar-alkyl, Het' or Het'-alkyl (where alkyl residues are optionally substituted by one or more F); b, c, d, f = 0 or 1 provided not all are 0; e, g,h = 0-6; Ar = optionally substituted 6-14C aryl; Het' = optionally substituted heteroaryl; unless specified otherwise alkyl moieties have 1-8C, alkenyl or alkynyl moieties 2-8C, cycloalkyl moieties 3-12C and bi- or tri-cycloalkyl moieties 6-12C.
-
-
-
-
-
-
-
-
-